Glycosylation in colorectal cancer: From tumor-intrinsic signaling to the host–microbiome glyco-interface
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189735
DOI: 10.1016/j.bbcan.2026.189735 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Yedu Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing 100044, China; Laboratory of Surgical Oncology, Beijing Key L…. Die Arbeit nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Peking University, National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Aberrant glycosylation is increasingly recognized as a key regulatory layer in colorectal cancer (CRC), extending beyond tumor-cell-intrinsic signaling to shape the tumor microenvironment and host-microbiome interactions. In the immune compartment, glycosylation modulates the stability and activity of classical checkpoints, including PD-L1, while tumor-associated glycans engage MGL, DC-SIGN, Siglecs, and galectins to form glyco-immune checkpoints that influence T-cell dysfunction, macrophage polarization, dendritic-cell tolerance, and NK-cell activity. These mechanisms support emerging glyco-immunotherapeutic strategies such as targeted desialylation, glycoform-specific targeting, and combination with immune checkpoint blockade. Glycosylation also functions as a molecular language at the host-microbiome interface. Site-specific epithelial glycoproteins, mucin O-glycoforms, bidirectional host-bacterial fucosylation, IgA-associated glycan recognition, and microbial glycan utilization may collectively shape CRC-associated dysbiosis and mucosal inflammation. Integrating stool glycoproteomics with microbiome profiling may further enable noninvasive screening and patient stratification. This review highlights glycosylation as a multidimensional interface linking tumor biology, antitumor immunity, and microbiome ecology, with implications for biomarker development and precision therapy in CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing 100044, China; Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Pekin…
Förderung
- Peking University
- National Key Research and Development Program of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wen, Y., Sun, H., Xiong, N., Xu, X., Ye, Y., Shen, Z., & Wang, C. (2026). Glycosylation in colorectal cancer: From tumor-intrinsic signaling to the host–microbiome glyco-interface. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189735. https://doi.org/10.1016/j.bbcan.2026.189735
Vancouver
Wen Y, Sun H, Xiong N, Xu X, Ye Y, Shen Z, et al. Glycosylation in colorectal cancer: From tumor-intrinsic signaling to the host–microbiome glyco-interface. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189735. doi:10.1016/j.bbcan.2026.189735
BibTeX
@article{Wen2026,
author = {Wen, Yedu and Sun, Haoyuan and Xiong, Nan and Xu, Xunye and Ye, Yingjiang and Shen, Zhanlong and Wang, Caihong},
title = {Glycosylation in colorectal cancer: From tumor-intrinsic signaling to the host–microbiome glyco-interface},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189735},
doi = {10.1016/j.bbcan.2026.189735}
}
EUVIMED